Sonrai Analytics, a leader in AI precision medicine, and AOA Dx, an early-stage biotech company developing what it says is the first test to diagnose ovarian cancer in symptomatic women, have announced a strategic partnership to accelerate the development of AOA’s multi-omic liquid biopsy test. The partnership aims to advance the development of the diagnostic test through a multi-omic biomarker validation strategy.
Through the partnership, AOA will leverage Sonrai’s cloud-based advanced analytics platform, pharma-grade data infrastructure and bioinformatic expertise to integrate and analyse multi-modal data, including multi-omic and clinical data. The platform will support AOA in validating diagnostic biomarkers, enhancing the accuracy and clinical utility of its serum-based test for ovarian cancer.
The test leverages a combination of novel gangliosides, lipids, and proteins to diagnose ovarian cancer in women experiencing vague abdominal symptoms. Diagnosing women when symptoms first occur could transform the pathway for women, and ultimately change outcomes, whilst offering significant savings to healthcare systems.
In addition, Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines, all within a secure, cloud-native environment. The Sonrai Discovery platform will enable AOA to store and manage their clinical data in role-based environments that allow controlled access, workspace isolation, cross-functional collaboration, and real-time performance tracking, to ensure security, governance, and compliance.
“We’re delighted to partner with AOA Dx to help advance the development of their innovative test for ovarian cancer. By applying our AI-powered analytics platform, we’re able to unlock deeper insights from complex multi-modal data, accelerating the validation of biomarkers, enabling earlier and more accurate detection,” said Prof. Darragh McArt, CEO and Founder, Sonrai Analytics.
“By partnering with Sonrai, we can not only integrate and manage our in-house development data but also cross-reference it with public datasets and analyses it seamlessly within one centralised environment,” said Dr Abigail McElhinny, Chief Scientific Officer, AOA Dx. “The ability to combine and analyse multi-omic, clinical, and demographic data within one compliant platform is critical to both our research and regulatory approval process.”
